How much revenue does the biologics contract development market generate?

The market revenue for biologics contract development is anticipated at USD 10.97 billion in 2027.

What is the projected value of the biologics contract development industry by 2036?

Biologics Contract Development Market size was worth USD 10.3 billion in 2026 and is expected to grow at a 7.7% CAGR between 2027 and 2036, crossing USD 21.63 billion by 2036.

Why is outsourcing becoming a strategic priority in the biologics contract development market?

Biopharma companies increasingly outsource development and manufacturing to access specialized expertise, flexible capacity, and integrated services that reduce development timelines while avoiding significant infrastructure investments.

How are complex biologics influencing demand for advanced contract development services?

Growing development of complex biologics and personalized therapies is increasing reliance on CDMOs with specialized capabilities in cell line engineering, process optimization, analytical characterization, and controlled manufacturing environments.

Why is Process Development the largest service segment in the biologics contract development market?

Process Development accounted for 70.56% of the market in 2026 because it is essential for manufacturability, scalability, regulatory readiness, and maintaining reliable biologic production performance throughout development.

What is driving the growth of microbial sources in the biologics contract development market?

Microbial sources are the fastest-growing segment as sponsors seek faster development timelines, cost-efficient manufacturing approaches, and flexible outsourcing models that support quicker process optimization.

Why does North America lead the biologics contract development market?

North America leads due to its strong biopharma base, advanced outsourcing networks, and deep capabilities in cell line development, process optimization, and analytical characterization services.

What is fueling Asia Pacific’s rapid growth in biologics contract development?

Asia Pacific is growing at 9.27% CAGR, driven by expanding biologics infrastructure, rising biopharma participation, and increasing outsourcing demand for scalable and cost-efficient development services.

What are the prominent companies operating in the biologics contract development landscape?

Top companies in the biologics contract development market include WuXi Biologics (China), Thermo Fisher Scientific Inc. (United States), Fujifilm Diosynth Biotechnologies U.S.A., Inc. (United States), AGC Biologics (Japan), KBI Biopharma, Inc. (United States), Boehringer Ingelheim Biopharmaceuticals GmbH (Germany), GenScript Biotech Corporation (China), Curia Global, Inc. (United States), Abzena Ltd. (United Kingdom), Samsung Biologics Co., Ltd. (South Korea).